论文部分内容阅读
目的:总结分析拉米夫定联合阿德福韦酯在乙肝肝硬化治疗中的应用效果。方法:选择2012年6月~2014年6月期间我院收治的90例乙肝肝硬化患者为研究对象,随机分为观察组和对照组各45例,对照组患者给予拉米夫定治疗,观察组患者给予拉米夫定与阿德福韦酯联合治疗,观察比较两组患者肝功能指标、肝脏Child-Pugh评分及不良反应情况。结果:治疗后观察组患者TBIL(35.2±6.8)μmol/L、AST(65.5±8.5)U/L、ALT(56.3±6.8)U/L及Child-Pugh评分(7.1±1.1)分均明显低于对照组,组间差异具有统计学意义(P<0.05);观察组HBV DNA转阴率73.33%、HBeAg转阴率28.33%均明显高于对照组,组间差异显著(P<0.05)。两组患者不良发生率相近(P>0.05)。结论:拉米夫定与阿德福韦酯联合治疗乙肝肝硬化效果显著,有助于改善肝功能,值得推广使用。
Objective: To summarize the application of lamivudine combined with adefovir dipivoxil in the treatment of hepatitis B cirrhosis. Methods: Ninety patients with hepatitis B cirrhosis admitted in our hospital from June 2012 to June 2014 were randomly divided into observation group (45 cases) and control group (45 cases). Patients in the control group were treated with lamivudine Group patients were given lamivudine and adefovir dipivoxil combination therapy, observed and compared liver function indicators, liver Child-Pugh score and adverse reactions. Results After treatment, the TBIL (35.2 ± 6.8) μmol / L, AST (65.5 ± 8.5) U / L, ALT (56.3 ± 6.8) U / L and Child-Pugh score (7.1 ± 1.1) The difference between the two groups was statistically significant (P <0.05). The negative rate of HBV DNA and the negative rate of HBeAg in the observation group were significantly higher than those in the control group (73.33%, 28.33%, P <0.05). The incidence of adverse reactions in both groups was similar (P> 0.05). Conclusion: The combination of lamivudine and adefovir dipivoxil is effective in treating liver cirrhosis, which is helpful to improve liver function and is worth popularizing.